At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 33 enrolled
Drug / intervention
GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of GSK2241658A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma
In Brief
A Phase 1 clinical trial evaluating GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI) for Melanoma. Completed, enrolled 33 participants across 24 sites in 8 countries.
Detailed Summary
The purpose of this study is to investigate the safety, immunogenicity and clinical activity of GSK2241658A antigen-specific cancer immunotherapeutic (ASCI) for the treatment of patients with non-operable and progressing metastatic cutaneous melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesAustralia, Austria, France, Germany, Italy, Netherlands, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartJan 2011
Primary CompletionApr 2018
TodayJul 2026
First PostedOct 4, 2010
Enrollment StartJan 31, 2011
Primary CompletionApr 17, 2018
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 15.7 years ago
Interventions
GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)biological
Up to 24 intramuscular administrations